2026 Q2 - tulosraportti
74 päivää sitten
‧32 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 12 254 | ||
| 1 200 | ||
| 6 212 | ||
| 3 000 | ||
| 13 823 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
3 t sittenJulkaisu on poistettu.
·27.10.ASN Kidney week in Denver was just held from Oct 21-25. And here KDIGO was on the field with various presentations of their upcoming new guidelines. From ChatGPT follows the following: Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) • Status: The brand new updates were officially presented and reviewed during ASN Kidney Week in October 2026. • Expected release: The full, final guideline (KDIGO 2026 AKI/AKD Guideline) will be officially released at the end of 2026. Subclinical AKI and "Supra-clinical" biomarkers A major theme at the conference in relation to the new KDIGO 2026 guidelines was the concept of subclinical AKI. This covers a condition where a patient has normal creatinine (and thereby technically does not meet the old criteria for renal failure), but has sky-high NGAL levels. Studies show that these patients have just as poor prognoses and high mortality as those with visible renal failure, which is why NGAL is now integrated to catch these "blind spots" in the clinic. So maybe this is the year that BioPorto finally gives us the Christmas present that we have been waiting for in 15-20 years 🙏KDIGO has sent out this teaser for the aforementioned conference/fair to inform relevant physicians and specialists that new guidelines for acute kidney injury are coming. Marlies Ostermann (Co-Chair for KDIGO's working group) is leading the presentation of the new recommendations, which fundamentally change the way kidney injuries are diagnosed, paving the way for the implementation of new kidney tests like the NGAL test into the regular treatment routines of doctors https://myemail.constantcontact.com/KDIGO-Direct.html?soid=1134196072483&aid=bDgMCLLdDMg
·27.10. · MuokattuThen you probably have to dig into your pockets again, if you do not want to be diluted Se https://borsen.dk/nyheder/investor/bioporto-vil-undga-endnu-en-kapitalrejsning-investor-ser-millionhul?b_source=borsen&b_medium=row_0&b_campaign=share_link_article Does anyone have an idea what their alternatives are? Bank loans? Bonds?
Now I am not going to take out a subscription to Børsen when someone has already read the article. But what does the article say that is not already known, one might ask. BioPorto hasn't announced that they need additional financing than the money they have in the cash register currently, or? So who raises questions about this in the article? The economy is tight - no doubt about this. If you do a quick calculation, it probably looks something like this: H1 26 - DKK minus 31 mil. Y2026 - DKK minus 60 mil. (maybe even more than that) H2 26 = 60-31 = DKK minus 29 mil. Cash H1 26 - DKK 76 mil. Rest to use in 2027 = 76 -29 = 47 mil. So there needs to be additional money in the cash register towards them being Cash Flow positive in 2028, if they are to use the same amount of money in 2027. Whether that can happen through increased sales or it requires external financing. Well, who knows? - with reasonable certainty none of us who write here.- ·23.10.Bioporto is making hay while the sun shines, I have lost count of how many trade fairs and conferences they have attended this year. I can see on their website that they are going to 3 more trade fairs this year. https://bioporto.com/events/For 5-6 years you have written with the same great enthusiasm about all the trade fairs and conferences they participate in. But you have looked at the price chart, right? It is only just a bit above the lowest it has ever been, so unfortunately there is nothing to suggest that they are gaining any particular value from those trade fairs. When you are in the kitchen, don't you also taste the food first before you add salt?
- ·23.10.It is very strange that 2 trades at 16.59 of respectively 2 and 7 pcs help to get the price from 1.025 to 0.994 - what is happening here ?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 286 613 | 286 613 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 286 613 | 286 613 | 0 | 0 |
2026 Q2 - tulosraportti
74 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 3 t sittenJulkaisu on poistettu.
- ·27.10.ASN Kidney week in Denver was just held from Oct 21-25. And here KDIGO was on the field with various presentations of their upcoming new guidelines. From ChatGPT follows the following: Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) • Status: The brand new updates were officially presented and reviewed during ASN Kidney Week in October 2026. • Expected release: The full, final guideline (KDIGO 2026 AKI/AKD Guideline) will be officially released at the end of 2026. Subclinical AKI and "Supra-clinical" biomarkers A major theme at the conference in relation to the new KDIGO 2026 guidelines was the concept of subclinical AKI. This covers a condition where a patient has normal creatinine (and thereby technically does not meet the old criteria for renal failure), but has sky-high NGAL levels. Studies show that these patients have just as poor prognoses and high mortality as those with visible renal failure, which is why NGAL is now integrated to catch these "blind spots" in the clinic. So maybe this is the year that BioPorto finally gives us the Christmas present that we have been waiting for in 15-20 years 🙏KDIGO has sent out this teaser for the aforementioned conference/fair to inform relevant physicians and specialists that new guidelines for acute kidney injury are coming. Marlies Ostermann (Co-Chair for KDIGO's working group) is leading the presentation of the new recommendations, which fundamentally change the way kidney injuries are diagnosed, paving the way for the implementation of new kidney tests like the NGAL test into the regular treatment routines of doctors https://myemail.constantcontact.com/KDIGO-Direct.html?soid=1134196072483&aid=bDgMCLLdDMg
- ·27.10. · MuokattuThen you probably have to dig into your pockets again, if you do not want to be diluted Se https://borsen.dk/nyheder/investor/bioporto-vil-undga-endnu-en-kapitalrejsning-investor-ser-millionhul?b_source=borsen&b_medium=row_0&b_campaign=share_link_article Does anyone have an idea what their alternatives are? Bank loans? Bonds?Now I am not going to take out a subscription to Børsen when someone has already read the article. But what does the article say that is not already known, one might ask. BioPorto hasn't announced that they need additional financing than the money they have in the cash register currently, or? So who raises questions about this in the article? The economy is tight - no doubt about this. If you do a quick calculation, it probably looks something like this: H1 26 - DKK minus 31 mil. Y2026 - DKK minus 60 mil. (maybe even more than that) H2 26 = 60-31 = DKK minus 29 mil. Cash H1 26 - DKK 76 mil. Rest to use in 2027 = 76 -29 = 47 mil. So there needs to be additional money in the cash register towards them being Cash Flow positive in 2028, if they are to use the same amount of money in 2027. Whether that can happen through increased sales or it requires external financing. Well, who knows? - with reasonable certainty none of us who write here.
- ·23.10.Bioporto is making hay while the sun shines, I have lost count of how many trade fairs and conferences they have attended this year. I can see on their website that they are going to 3 more trade fairs this year. https://bioporto.com/events/For 5-6 years you have written with the same great enthusiasm about all the trade fairs and conferences they participate in. But you have looked at the price chart, right? It is only just a bit above the lowest it has ever been, so unfortunately there is nothing to suggest that they are gaining any particular value from those trade fairs. When you are in the kitchen, don't you also taste the food first before you add salt?
- ·23.10.It is very strange that 2 trades at 16.59 of respectively 2 and 7 pcs help to get the price from 1.025 to 0.994 - what is happening here ?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 12 254 | ||
| 1 200 | ||
| 6 212 | ||
| 3 000 | ||
| 13 823 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 286 613 | 286 613 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 286 613 | 286 613 | 0 | 0 |
2026 Q2 - tulosraportti
74 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- 3 t sittenJulkaisu on poistettu.
- ·27.10.ASN Kidney week in Denver was just held from Oct 21-25. And here KDIGO was on the field with various presentations of their upcoming new guidelines. From ChatGPT follows the following: Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) • Status: The brand new updates were officially presented and reviewed during ASN Kidney Week in October 2026. • Expected release: The full, final guideline (KDIGO 2026 AKI/AKD Guideline) will be officially released at the end of 2026. Subclinical AKI and "Supra-clinical" biomarkers A major theme at the conference in relation to the new KDIGO 2026 guidelines was the concept of subclinical AKI. This covers a condition where a patient has normal creatinine (and thereby technically does not meet the old criteria for renal failure), but has sky-high NGAL levels. Studies show that these patients have just as poor prognoses and high mortality as those with visible renal failure, which is why NGAL is now integrated to catch these "blind spots" in the clinic. So maybe this is the year that BioPorto finally gives us the Christmas present that we have been waiting for in 15-20 years 🙏KDIGO has sent out this teaser for the aforementioned conference/fair to inform relevant physicians and specialists that new guidelines for acute kidney injury are coming. Marlies Ostermann (Co-Chair for KDIGO's working group) is leading the presentation of the new recommendations, which fundamentally change the way kidney injuries are diagnosed, paving the way for the implementation of new kidney tests like the NGAL test into the regular treatment routines of doctors https://myemail.constantcontact.com/KDIGO-Direct.html?soid=1134196072483&aid=bDgMCLLdDMg
- ·27.10. · MuokattuThen you probably have to dig into your pockets again, if you do not want to be diluted Se https://borsen.dk/nyheder/investor/bioporto-vil-undga-endnu-en-kapitalrejsning-investor-ser-millionhul?b_source=borsen&b_medium=row_0&b_campaign=share_link_article Does anyone have an idea what their alternatives are? Bank loans? Bonds?Now I am not going to take out a subscription to Børsen when someone has already read the article. But what does the article say that is not already known, one might ask. BioPorto hasn't announced that they need additional financing than the money they have in the cash register currently, or? So who raises questions about this in the article? The economy is tight - no doubt about this. If you do a quick calculation, it probably looks something like this: H1 26 - DKK minus 31 mil. Y2026 - DKK minus 60 mil. (maybe even more than that) H2 26 = 60-31 = DKK minus 29 mil. Cash H1 26 - DKK 76 mil. Rest to use in 2027 = 76 -29 = 47 mil. So there needs to be additional money in the cash register towards them being Cash Flow positive in 2028, if they are to use the same amount of money in 2027. Whether that can happen through increased sales or it requires external financing. Well, who knows? - with reasonable certainty none of us who write here.
- ·23.10.Bioporto is making hay while the sun shines, I have lost count of how many trade fairs and conferences they have attended this year. I can see on their website that they are going to 3 more trade fairs this year. https://bioporto.com/events/For 5-6 years you have written with the same great enthusiasm about all the trade fairs and conferences they participate in. But you have looked at the price chart, right? It is only just a bit above the lowest it has ever been, so unfortunately there is nothing to suggest that they are gaining any particular value from those trade fairs. When you are in the kitchen, don't you also taste the food first before you add salt?
- ·23.10.It is very strange that 2 trades at 16.59 of respectively 2 and 7 pcs help to get the price from 1.025 to 0.994 - what is happening here ?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 12 254 | ||
| 1 200 | ||
| 6 212 | ||
| 3 000 | ||
| 13 823 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 286 613 | 286 613 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 286 613 | 286 613 | 0 | 0 |